Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SetPoint Launches IDE Trial Of Vagus Nerve Stimulation To Treat Arthritis

Executive Summary

The randomized trial will evaluate SetPoint's bioelectronic platform in patients with moderate-to-severe rheumatoid arthritis, supported by funds secured in a recent preferred stock financing.

You may also be interested in...



Industry Praises CMS Final MCIT Reimbursement Rule; Urges Biden Team To Implement It

The US Medicare agency issued on 12 January its final MCIT rule allowing instant reimbursement for FDA breakthrough devices – unless the incoming Biden administration blocks it.

Start-Up Spotlight: SetPoint Develops Vagus Nerve Stimulation To Treat Crohn's Disease And Rheumatoid Arthritis

SetPoint Medical is developing vagus nerve stimulation technology for Crohn’s disease and rheumatoid arthritis and believes it will be a "platform technology" for treating a variety of autoimmune diseases.

SetPoint Medical Starts Testing Unique Neuromodulation Device In Rheumatoid Arthritis Patients

SetPoint Medical announced the launch of a multicenter clinical trial to test its vagus nerve stimulation system in rheumatoid arthritis patients who did not adequately respond to multiple biologic agents. Among the company's backers are Medtronic, Boston Scientific and GSK.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143474

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel